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Background: Randomized clinical trials (RCTs) have
demonstrated the efficacy of implan-table cardiover-
ter-defibrillators (ICDs) in reducing sudden cardiac
death (SCD) in specific patient populations. Howe-
ver, patients ≥ 65 years were under-represented in
these trials and the overall benefit of ICDs may be
diminished in older patients due to competing risks
for death. We evaluate the published data on ICD
efficacy at reducing all-cause mortality in patients
≥ 65 years and in patients ≥ 75 years.
Methods: We searched MEDLINE to identify RCTs
and observational studies of ICDs that provided age-
based outcome data for primary prevention of SCD.
The primary endpoint was mortality evaluated by
a meta-analysis of the RCTs using a random-effects
model. Secondary endpoints included operative
mortality, long-term complications and quality of life.
Results: The enrollment of patients ≥ 65 years in
RCTs was limited (range: 33% in DEFINITE to 56% in
MUSTT). Combining data from four RCTs (n = 3,562)
revealed that primary prevention ICD therapy is ef-
ficacious in reducing all-cause mortality in patients
≥ 65 ye-ars (HR 0.66; 95% CI 0.50–0.87; test of hete-
rogeneity: X2 = 5.26; p = 0.15). For patients ≥ 75
years, combining data from four RCTs (n = 579) re-
vealed that primary prevention ICD therapy remains
efficacious in reducing all-cause mortality (HR 0.73;
95% CI 0.51–0.974; p = 0.03). There appears to be no
difference in ICD-related, operative, in-hospital, or
long-term complications among older patients com-
pared to younger patients, although it remains unc-
lear if older patients have a better quality of life with
an ICD than younger patients.
Conclusions: Although the overall evidence regar-
ding ICD efficacy in patients ≥ 65 years is limited and
divergent, and the evidence available for patients
≥ 75 years is even more sparse, our meta-analysis
suggests that primary prevention ICDs may be be-
neficial in older patients. Our findings need to be
validated by future studies, particularly ones exami-
ning ICD complications and quality of life. (Cardiol
J 2011; 18, 5: 503–514)
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INTRODUCTION
In the United States, sudden cardiac death (SCD) ac-
counts for more than 350,000 deaths annually, dispropor-
tionately affecting those aged ≥ 65 years [1]. Currently,
implantable cardioverter-defibrillators (ICDs) are the most
effective treatment for patients at high risk of SCD. As
a result, their use rose 20–30% annually throughout the
1990s [2]. However, individual randomized controlled
trials (RCTs) of ICDs enrolled relatively few patients aged
65 years or older, and even fewer of these patients were
aged 75 years or older [3–10]. Thus, the optimal use of ICDs
in the older population remains uncertain.
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Clinically, patients aged ≥ 65 years are distinctly different
from their younger cohorts. Advanced age is often accompa-
nied by greater susceptibility to complications and adverse
effects of therapies, as well as more co-morbidities and mul-
ti-system diseases that increase the risk of non-SCD. Conse-
quently, the risks of ICD implantation may be higher and the
potential benefits of ICD therapy may be reduced in this pa-
tient population [11]. Given the limited evidence and the
potential for disparate risks and benefits in this population,
we conducted a systematic review of the published literatu-
re to evaluate the body of evidence addressing the use of ICDs
in patients aged ≥ 65 years and performed the first formal
meta-analysis of the primary prevention trials in the growing
subpopulation of patients aged ≥ 75 years.
METHODS
Data sources and study selection
We conducted a systematic search of MEDLINE, Co-
chrane Controlled Trials Register, clinicaltrials.gov, and
fda.gov using the terms “defibrillator” or “clinical trial”
(Fig. 1). Limiting our search to peer-reviewed studies per-
formed in humans and published in English since 1 Janu-
ary, 1990, we identified 1,540 potentially relevant citations,
of which 1,306 were excluded at the abstract screening sta-
ge. Studies of cardiac resynchronization therapy, studies
that included ICD therapy in both treatment and control
arms, and studies lacking estimates of ICD effect based on
age were excluded (n = 1,306). Studies enrolling < 100 pa-
tients or lacking age subgroup analyses were also excluded
(n = 195), leaving 39 studies for review. Of these, seconda-
ry prevention RCTs and substudies or meta-analyses of se-
condary prevention RCTs were excluded (n = 8). A review
of the references cited in the remaining 31 studies did not
identify any additional studies that met inclusion criteria.
Non-randomized prospective or retrospective case
series investigating the effectiveness of ICDs based on age
(n = 6) were found and included in the literature review,
along with publications of primary prevention RCTs (n = 9)
and their substudies (n = 10). However, only RCTs were
included in the meta-analysis. Of the nine primary pre-
vention RCTs, only five were selected for the meta-analy-
sis. Of the four RCTs that were excluded, CAT and AMIO-
VIRT were excluded due to lack of estimates of ICD effect
based on age, and DINAMIT and CABG-PATCH were
excluded a priori due to their enrollment of markedly diffe-
rent patient populations than the RCTs that were included.
Due to this significant heterogeneity, including DINAMIT
and CABG-PATCH in the meta-analysis would not be va-
lid. Additionally, COMPANION was not included in our
meta-analysis because this trial was designed to evaluate
cardiac resynchronization therapy, and not ICD therapy.
Data extraction and synthesis
Abstracts of identified studies were reviewed indepen-
dently by two investigators (MHK, GDS). We abstracted
data from each article on study design, treatment, patient
and clinical characteristics, outcomes, subgroup findings,
ICD complications, and quality of life (QoL). Discrepancies
between reviewers were resolved through discussion. For
the meta-analysis, the primary outcome of interest was all-
cause mortality in patients ≥ 65 years old. Although not eve-
ry study included in the meta-analysis provided the subgro-
up analysis for patients ≥ 65 years or for patients ≥ 75 years,
we obtained these data for each RCT from the trials’ princi-
pal investigators. Likewise, for the overall review, the primary
endpoint was mortality. Secondary endpoints included ope-
rative mortality, long-term complications and QoL.
Statistical methods
To be included in the meta-analysis, all studies had to
be randomized clinical trials with an appropriate control
analyzed by the intention-to-treat principle. Using an
empirical Bayes random-effects estimator, we combined
trial-level data on older patients from the major RCTs of
primary prevention ICDs, which represent populations for
which ICDs are recommended [12]. When no heterogene-
ity is present, this estimator reduces to a fixed effects esti-
mator. The estimates were computed using Comprehensi-
ve Meta-Analysis SoftwareTM (BIOSTAT, Englewood, NJ,
USA). Statistical heterogeneity was measured using the c2
test. Statistical tests were two-tailed, and statistical signifi-
cance was declared at p < 0.05. We did not combine data on
older patients from the major RCTs of secondary preven-
tion ICDs as this has been done previously [13].
RESULTS
ICDs for primary prevention of SCD
in patients aged 65 years and older
Table 1 presents data on the mean age of patients en-
rolled in the nine RCTs of primary prevention ICDs [3–9,
14, 15].  The number of patients ≥ 65 years ranged from
55% in the Multicenter Unsustained Tachycardia Trial
(MUSTT) to 34% in the Defibrillators in Non-Ischemic Car-
diomyopathy Treatment Evaluation (DEFINITE) trial [16].
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Defibrillator in Acute Myocardial Infarction Trial (DINAMIT)
data was not available. Five RCTs provided data on primary
prevention ICDs in patients ≥ 65 years (Table 2) [1, 6, 8, 9, 17,
18]. Of these trials, MUSTT enrolled the highest percentage
of patients > 65 years (55.97%) and the oldest patient popu-
lation (mean age 66 years) [7]. A MUSTT substudy explored
the effect of age on ICD benefit by examining 243 patients
aged ≥ 70 years and showed that the benefit from ICD the-
rapy was similar in older and younger patients [17].
The Multicenter Automatic Defibrillator Implantation
Trial-II (MADIT-II) randomized patients with a prior my-
ocardial infarction and left ventricular ejection fraction
(LVEF) £ 30% to ICD therapy or conventional medical
therapy. Of this population, 1,028 patients were < 75 years
of age, and 204 patients were ≥ 75 years of age. Hazard
ratios (HR) for the three predefined age subsets were 0.46
for age < 60 years; 0.77 for age 60–69 years; and 0.65 for
age ≥ 70 years [6]. Subsequently, two substudies from
MADIT-II addressed the effect of age on ICD efficacy (Ta-
ble 2) [1, 18]. Patients aged ≥ 75 ye-ars in MADIT-II had
a HR of 0.56 compared with conventional therapy (95% CI
0.29–1.08; p = 0.08) [18]. The second substudy re-exami-
ned the pre-specified age subgroups (< 65, 65–74, and
≥ 75 years of age) to assess ICD benefit with respect to age
[1]. In patients aged ≥ 75 years, there was a 68% reduction
in the risk of SCD with ICD therapy and this finding was
similar in patients aged 65–74 years. The greatest benefit
of ICD therapy for all-cause mortality was seen in the gro-
Figure 1. QUOROM flowchart; CRT — cardiac resynchronization therapy; ICD — implantable cardioverter-defibrillator; RCT
— randomized clinical trials
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Table 1. Randomized controlled trials of implantable cardioverter-defibrillator (ICD) therapy in primary prevention of sud-
den cardiac death
Trial (year) Treatment Patients Mean age Patients Hazard ratio for effect
group  (years)  ≥ 65 y/o (%)  of ICD therapy on
all-cause mortality (95% CI)
MADIT-I (1996) [5] Total 196 63 ± 9* 53.5 0.46 (0.26–0.82)
ICD 95 62 ± 9 53.5
Control 101 64 ± 9 53.5
CABG-PATCH (1997) [4] Total 900 64 ± 9* 49.89 1.07 (0.81–1.42)
ICD 446 64 ± 9 50.0
Control 454 63 ± 9 50.0
MUSTT (1999) [7] Total 704 66.5*† 55.97 0.45 (0.32–0.63)
ICD 161 65.4 (8.52)‡ 56.9
Control 543 64.9 (9.65)‡ 54.1
CAT (2002) [14] Total 104 52 ± 11 NR 0.83 (0.45–1.52)
ICD 50 52 ± 12 NR
Control 54 52 ± 10 NR
MADIT-II (2002) [6] Total 1,232 64 ± 10* 48.0 0.69 (0.51–0.93)
ICD 742 64 ± 10 44.2
Control 490 65 ± 10 51.4
AMIOVIRT (2003) [15] Total 103 NR NR NR
ICD 51 58 ± 11 NR
Control 52 60 ± 12 NR
DINAMIT (2004) [3] Total 674 62 ± 11* NR 1.08 (0.76–1.55, p = 0.66)
ICD 332 61.5 ± 10.9 NR
Control 342 62.1 ± 10.6 NR
DEFINITE (2004) [8] Total 458 58.3 34.28 0.65 (0.40–1.06, p = 0.08)
ICD 229 58.4 35.4
Control 229 58.1 33.2
SCD-HeFT (2005) [9] Total 2,521 60*† 34.49 0.77 (0.62–0.96, p = 0.007)§
ICD 829 60.1† 35.5
Control (amiodarone) 845 60.4† 33.5
Control (placebo) 847 59.7†
NR — not reported; *values not reported in original trial publications, but obtained from reference [45]; †median; ‡mean (standard deviation); §97.5% confidence
interval (CI)
up aged 65–74 years, who experienced a 37% reduction
(p = 0.03), while younger patients experienced a 21% re-
duction (p = 0.35), and older patients a 30% reduction
(p = 0.20). However, these results also need to be interpre-
ted cautiously given the known limitations of subgroup
analyses [19].
The DEFINITE trial comprised exclusively patients
with non-ischemic cardiomyopathy and thus enrolled
a younger patient population, with a mean age of 58 years.
DEFINITE suggested that patients aged ≥ 65 years deri-
ved similar benefit from ICD therapy as did their younger
counterparts [8].
An age-related subgroup analysis of the Sudden Car-
diac Death in Heart Failure Trial (SCD-HeFT) showed gre-
ater benefit in ICD recipients < 65 years [9]. The largest of
the primary prevention trials, SCD-HeFT enrolled 2,521
patients with NYHA class II–III congestive heart failure and
an LVEF ≥ 35% and randomized patients to placebo, amio-
darone, or a single-lead ICD [9]. Compared to placebo, ICD
therapy resulted in a 23% reduction in risk of death. For the
group aged ≥ 65 years, ICD implantation compared to pla-
cebo carried a favorable HR of 0.86, but the 97.5% CI cros-
sed unity (0.62–1.18), reflecting the smaller sample size of
the older age group (n = 578) compared to their younger
counterparts (n = 1,098; HR 0.68; 97.5% CI 0.50–0.93).
Combining data from MADIT-I, MADIT-II, DEFINITE,
and SCD-HeFT, we found ICDs to be efficacious in redu-
cing all-cause mortality in patients ≥ 65 years (HR 0.66;
95% CI 0.50–0.87; test of heterogeneity: X2 = 5.26; p = 0.15).
When we included the MUSTT trial, ICD therapy was still
efficacious in reducing all-cause mortality (HR 0.60; 95%
CI 0.45–0.78); however, there was a trend toward signifi-
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Table 2. Effect of age on implantable cardioverter-defibrillator (ICD) efficacy in substudies and subgroup analyses from
randomized clinical trials of ICD therapy for the primary prevention of sudden cardiac death (SCD)
Author (year) Parent trial Age Patients Hazard ratio for effect
subgroups  of ICD therapy on all-cause
(years)  mortality (95% CI)
Moss (1996) [5] MADIT-I None 196 For patients ≥ 65: 0.38 (0.17–0.86)*
Bigger (1997) [4] CABG-PATCH None 900 No significant difference in HR for ICD
 group compared to control therapy
 in subgroup analysis stratified by
 age. However, for patients ≥ 65:
1.216 (0.858–1.724)*
Moss (2002) [6] MADIT-II < 60 370 0.46 (0.23–0.93)†
60–69 426 0.77 (0.47–1.25)†
≥ 70 436 0.65 (0.42–0.98)†
Peterson (2003) [17]§ MUSTT < 70 461 0.52 (0.33–0.77)†
≥ 70 243 0.43 (0.27–0.80)†
Greenberg (2004) [48] MADIT-II None 1,232 0.33 (0.20–0.53, p < 0.0001).
No significant difference in
reduction of SCD by ICD in
subgroup analysis stratified by age
Kadish (2004) [8] DEFINITE < 65 301 0.70 (0.35–1.40)†
≥ 65 157 0.63 (0.32–1.23)†
Hohnloser (2004) [3] DINAMIT < 60 275 HR < 1.0, 95% CI crosses 1.0‡
≥ 60 399 For patients ≥ 65: 1.23 (0.82–1.84)*
Bardy (2005) [9] SCD-HeFT < 65 1,098 0.68 (0.50–0.93)
≥ 65 578 0.86 (0.62–1.18)
Huang (2007) [18] MADIT-II < 75 1,028 0.63 (0.45–0.88, p = 0.01)
≥ 75 204 0.56 (0.29–1.08, p = 0.08)§
Goldenberg (2007) [1] MADIT-II < 65 574 0.79 (0.48–1.29)
65–74 455 0.63 (0.41–0.95)
≥ 75 204 0.70 (0.41–1.20)§
NA — not applicable; *hazard ratios (HR) and confidence intervals (CI) not published, but obtained from personal communication with trial investigators; †HR and CI
not reported in original trial publications, but obtained from reference [45]; ‡exact point estimates have not been published; §these published point estimates for the
204 patients in MADIT-II ≥ 75 years of age are different because each was derived using a different statistical model
cant heterogeneity among the trials (X2 = 8.01; p = 0.09)
(Figs. 2A, B). This increased heterogeneity may reflect the
fact that, unlike the other trials included, ICD therapy was
not randomized in MUSTT.
ICDs for primary prevention of SCD
in patients aged 75 years and older
The number of patients ≥ 75 years ranged from 17%
in MADIT-II to 9% in MADIT-I, DEFINITE, and SCD-HeFT
alike (Table 3) [5, 6, 8, 9]. Four RCTs provided data on pri-
mary prevention ICDs in patients ≥ 75 years (Table 3) [6–9].
There were no deaths among the 18 patients aged ≥ 75
years randomized to the ICD treatment arm of MADIT-I,
and as such a HR was not calculable [5]. Combining data
from MUSTT, MADIT-II, DEFINITE, and SCD-HeFT, we
found that ICDs remained efficacious in reducing all-cause
mortality in patients ≥ 75 years (HR 0.73; 95% CI 0.51–
–0.974; p = 0.03) (Fig. 3).
Non-randomized studies of ICDs
in older patients
Numerous non-randomized studies have attempted
to examine the efficacy of ICD implantation in older pa-
tients (Table 4) [20–24]. One study examined patients who
received ICDs for primary prevention indications. Others
included both secondary and primary prevention indica-
tions. A few studies included patients who had received
an ICD for either secondary or primary prevention indi-
cations [20–24]. Two of these studies found ICDs to be of
similar effectiveness in older and younger patients [20, 22],
and three studies found that younger patients derived
more benefit than older patients [21, 23, 24]. These studies
were limited by small sample sizes, non-randomized de-
sign, and lack of appropriate adjustment for different so-
urces of bias.
Only one study was limited to patients with a primary
prevention indication for an ICD [25]. This study prospec-
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tively enrolled 965 patients, with or without an ICD, and
with either ischemic or non-ischemic cardiomyopathy.
Using a landmark analysis and multivariable Cox propor-
tional hazards models that included propensity scores for
ICD implantation, this study showed that ICD use was
associated with lower all-cause mortality, even among
older patients and those with co-morbid conditions [25].
In-hospital complications
in patients aged 65 and older
Of all patients receiving an ICD, about 30% experience
one or more complications post-implantation, 10% of which
are directly related to the implantation procedure [26]. The
inherent risks of ICD implantation must therefore be con-
sidered when evaluating their potential use in older pa-
tients [27]. Although sparse, current evidence suggests that
ICD operative mortality may be independent of age. In one
case series of consecutive patients referred to a single insti-
tution for ICD implantation, mortality was similar in pa-
tients aged ≥ 70 years vs < 70 years [28].
Complications related to ICD implantation include
atrial or ventricular lead dislodgement or fracture, devi-
ce migration or malfunction, pneumothorax, damage to
arteries and nerves, air embolism, vein thrombosis, car-
diac perforation and resultant pericardial effusion with
or without tamponade, pocket hematoma, pocket or sys-
temic infection, and arrhythmias related to lead manipu-
lation [29]. A study of Medicare Provider Analysis and
Review (MedPAR) files from fiscal year 2003 analyzed
31,000 Medicare beneficiaries receiving ICDs as an iso-
Figure 2. Hazard ratios for all-cause mortality in patients ≥ 65 years with MUSTT (A) and without MUSTT (B)
Table 3. Randomized controlled trials of implantable cardioverter-defibrillator (ICD) therapy in primary prevention of sud-
den cardiac death
Trial (year) Patients Patients Patients Hazard ratio for effect
≥ 75 y/o (n)  ≥ 75 y/o (%)  of ICD therapy on all-cause
mortality (95% CI)
MADIT-I (1996) [5] 196 18 9.18 No deaths in ICD treatment arm
MUSTT (1999) [7] 704 96 13.6 1.00 (0.58–1.75)
MADIT-II (2002) [6] 1,232 204 16.6 0.71 (0.42–1.19)
DEFINITE (2004) [8] 458 43 9.4 0.29 (0.09–0.97)
SCD-HeFT (2005) [9] 2,521 236 9.4 0.65 (0.39–1.05)
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lated procedure in 2002–2003. It found that the rate of
one or more in-hospital complications related to ICD
implantation was 10.8% [30]. In this study, the age distri-
bution was similar among patients who experienced
complications compared to those who did not. Another
retrospective database analysis of prospectively collected
data from a single center stratified patients into two gro-
ups: patients aged 70–79 years and ≥ 80 years [20]. Except
for age, the two groups were similar demographically, and
had similar actuarial survival rates and complication rates
(p = 0.16). A third retrospective case series of 450 patients
who underwent ICD implantation at a single center found
that perioperative mortality by age group was not signi-
ficantly different among age groups [11].
More recently, a study of Medicare beneficiaries who
received an ICD between 2002 and 2005 examined patient
and implanting physician factors associated with the out-
comes of ICD implantation [31]. The mean age of the
8,581 patients who had an ICD implanted during the stu-
dy period was 75 years. Age was not found to be an in-
dependent risk factor for increased complications [31].
Long-term ICD complications
in patients aged 65 and older
Little is known about the long-term complications of
ICD therapy in the general population, and as such, even
less can be extrapolated to older patients. Based on data
from 500 consecutive patients enrolled in the Marburg
Defibrillator Database, rates of inappropriate shocks over
a 48 month period were similar for patients aged ≥ 75
years compared to patients aged < 75 years (3% vs 13%;
p = 0.29) [23]. Rates of generator-related complications and
total mortality were higher among the older subgroup com-
pared to the younger subgroup (33% vs 20%; p = 0.01).
However, the number of older patients was very small,
making the true long-term complication rate uncertain.
In the aforementioned study on patient and implan-
ting physician factors associated with outcomes of ICD
therapy in Medicare beneficiaries, the one-year mortali-
ty rate declined from 16.4% in 2002 to 13.2% in 2005 (p <
< 0.001) [31]. Older age was found to be independently asso-
ciated with an increased risk of one-year mortality. Addi-
tional risk factors for increased mortality included history
of myocardial infarction, congestive heart failure, chronic
lung disease, dementia, diabetes, metastatic cancer, peri-
pheral vascular disease, renal disease, and admission from
the emergency room, many of which are more often found
in older patients with significant co-morbid illnesses.
Effect of age on quality of life
in ICD patients
Equally important to understanding the morbidity
and mortality risks associated with ICD implantation are
the QoL implications of ICDs in older patients. Three of the
large RCTs have systematically examined the impact of
ICD therapy on QoL — MADIT-II, CABG-PATCH, and
most recently, SCD-HeFT [32–36]. However, short follow-
-up and methodological issues have limited the value of
these substudies. Furthermore, it remains unclear how
ICDs affect QoL in patients who receive primary preven-
tion ICDs [36]. The largest QoL study in ICD recipients for
primary prevention of SCD was performed in the SCD-
-HeFT population; however, the effect of age on QoL was
not examined.
The only study that examined the relationship betwe-
en age and QoL in the setting of a RCT was a MADIT-II
substudy that included 1,089 patients and measured He-
alth Utility Index-3 scores at three, 12, 24, and 36 months
following enrollment [35]. Mean patient age in this substu-
dy was approximately 65 years. Patients in the control
group maintained a steady health-related quality of life
(HRQOL), while ICD patients showed a gradually dimi-
Figure 3. Hazard ratios for all-cause mortality in patients ≥ 75 years
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nishing HRQOL. The declining average HRQOL in the
control group was only due to mortality, but in the ICD
group it was due to both mortality and decreasing
HRQOL values for survivors. The difference in quality
adjusted life years (QALY) between the two groups was
not statistically significant. Within this study, key subgro-
up analyses were performed and for patients ≥ 65 years
there was no significant decrease in QALYs while alive.
The relationship between age and QoL has been exami-
ned in several non-randomized studies [18, 35, 37, 38]. These
studies were limited by small sample size, non-randomized
study design, and lack of adjustment for potential confoun-
ders. Nonetheless, in general, these studies showed that
although older patients with ICDs had decreased physical
functioning, more co-morbid illness, and worse symptoms
that negatively impact QoL, younger patients with ICDs
tended to experience increased psychological distress,
anxiety, and depression, which negatively impact QoL.
DISCUSSION
With the aging of the US population, expanding indi-
cations for ICD implantation, and growing evidence favo-
ring device-based therapy over antiarrhythmic drugs,
data on the utilization and efficacy of ICDs in older pa-
tients is becoming increasingly important.
Despite the growing body of evidence from numero-
us large RCTs demonstrating that ICDs improve survival
rates in various subsets of patients, the mean age of the
patients enrolled in the RCTs of primary prevention ICDs
was < 65 years and no RCT has prospectively focused on
evaluating the outcomes and efficacy of these devices in
patients aged ≥ 65 years, much less in those patients aged
≥ 75 years. In fact, some trials have purposely excluded
patients over 80 years of age [3, 4, 39]. Still, conclusions
about the impact of ICDs for the primary prevention of
SCD in older patients are often extrapolated from such
studies performed in these younger patient subgroups
with mean ages much less than 65 years. In light of the
established guidelines, an RCT specifically addressing
ICD therapy in the older population is unlikely to be per-
formed. Our meta-analysis and systematic literature re-
view highlights the considerable under-representation
of older patients in the available RCTs. Additionally, the
validity of the non-randomized, retrospective studies is
unclear, since they did not adjust for inherent selection
biases and their study populations consisted of patients
who had already been referred for, or had already rece-
ived, ICD therapy.
Given the limited number of older patients enrolled in
the primary prevention RCTs of ICD therapy, we combi-
ned data from four major RCTs of primary prevention
ICDs (MADIT-I, MADIT-II, DEFINITE, and SCD-HeFT).
We chose these trials to minimize heterogeneity because
all of them randomized patients to ICD vs a control arm,
and the patients enrolled were similar. The results of our
meta-analysis are concordant with a recent qualitative
overview that concluded that the relative benefit of ICD
therapy is somewhat higher in older than in younger pa-
tients in MADIT-II, MUSTT, and DEFINITE; somewhat
lower in older than in younger patients in SCD-HeFT; and
equivocal, but tending toward harm, in the older group
compared to the younger group in DINAMIT [40]. A few
studies have examined the effect of age at implantation on
outcomes after ICD implantation. Most trials only provi-
de follow-up data ranging from 3–6 years, so longer-term
outcomes remain largely unknown [36]. Likewise, very
little is known about the physical, emotional, and social
adjustments associated with ICD implantation and the
impact of age on these factors. As such, concerns are fre-
quently raised about the effect of advanced age on the
outcomes, cost–effectiveness, and QoL of such patients
who receive ICDs. Based on our review of the literature,
there appears to be no difference in operative, in-hospi-
tal, or long-term complications among older patients com-
pared to younger patients [11, 18, 20, 23, 28].
One of the goals of our paper was to highlight the fact
that there is extremely little QoL data on the use of ICDs
in older patients — a subpopulation in which QoL is often
a critical factor in clinical decision making. At this time, it
remains unclear if older patients actually have a better
QoL with an ICD than younger patients [35, 37, 41–44].
Two qualitative reviews have addressed the use of
ICDs in older patients [1, 45]. Each review describes RCTs
of ICD therapy for both secondary and primary preven-
tion and includes descriptions of a few non-randomized
cohort studies of ICD therapy in older patients. In contrast,
our systematic literature review provides the first and only
formal meta-analysis of data on patients ≥ 65 years and
≥ 75 years from the major RCTs on primary prevention
ICDs. Additionally, our review examines in more detail
both perioperative and long-term complications in older
patients, and considers the effect of age on QoL in patients
with ICDs.
In contrast to our findings, a recently published meta-
analysis by Santangeli et al. [46] examined the effective-
ness of ICDs for the primary prevention of SCD in older
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patients using data from MADIT-II, DEFINITE, and SCD-
-HeFT and found only a minimal and statistically non-signifi-
cant survival benefit in older patients (HR 0.81; 95% CI 0.62–
1.05; p = 0.11). However, the analysis by Santangeli et al. [46]
defined older patients as those ≥ 60 years of age, combined
data from one study for patients ≥ 60 years old with data from
other studies for patients ≥ 65 years old, and did not include
data from the MADIT-I and MUSTT trials of primary preven-
tion, citing the unavailability of this data.
While RCTs will provide the strongest data on ICDs in
patients ≥ 65 years, data on ICD benefit in older patients
can be gleaned from registries of patients in the general
population. One such registry is the American College of
Cardiology-National Cardiovascular Data Registry (ACC-
-NCDR)-operated National ICD Registry. Since Medica-
re patients account for 70% of all patients entered into the
National ICD Registry, this registry provides a unique
opportunity to address key questions relevant to clinical
practice that remain unanswered by the numerous, large
RCTs [47]. Long-term outcomes data will be evaluated by
combining the ICD Registry with the Medicare Claims
Database and potentially with the National Death Index
and as such, the National ICD Registry will more accura-
tely reflect the costs and outcomes of ICDs implanted in
older patients seen in general clinical practice compared
to the highly selected, younger patient populations with
fewer co-morbidities typically enrolled in RCTs [38]. Al-
though this data will be useful, one limitation of this type
of data source is the lack of a control group, because eve-
ryone enrolled in the registry will have received an ICD.
Our study has some limitations. As with any literature
search of databases like PubMed, publication bias cannot be
excluded and our inclusion of only published, peer-revie-
wed studies contributes to selection bias. Similarly, our de-
cision to meta-analyze only RCTs may not reflect patients
in general clinical practice because trial populations are
often highly-selected patient subgroups. Finally, the lack of
patient-level data precluded more detailed analyses such
as examination of the extremely small subgroup of octoge-
narians who received primary prevention ICDs.
CONCLUSIONS
In contrast to a previously published age-specific
meta-analysis demonstrating a lack of ICD efficacy for the
secondary prevention of SCD in patients ≥ 75 years, our
meta-analysis of ICD use for primary prevention of SCD
suggests that ICDs may be beneficial for older patients,
including those patients ≥ 75 years.
Given that the current data supporting the efficacy of
ICD therapy in older patients is sparse and inconclusive,
implanting an ICD in an older patient should be a decision
made between the patient and the physician, which takes
into account each individual’s overall health status, co-
-morbidities, physical and mental functioning, and perso-
nal preferences. The use of ICDs in older patients should
not be withheld based on age alone.
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